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ABSTRACT
Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage 
repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have 
demonstrated clinical proof of concept for cancer treatment. Here, we describe 
the development of the novel PARP inhibitor E7449, a potent PARP1/2 inhibitor 
that also inhibits PARP5a/5b, otherwise known as tankyrase1 and 2 (TNKS1 
and 2), important regulators of canonical Wnt/β-catenin signaling. E7449 inhibits 
PARP enzymatic activity and additionally traps PARP1 onto damaged DNA; a 
mechanism previously shown to augment cytotoxicity. Cells deficient in DNA repair 
pathways beyond homologous recombination were sensitive to E7449 treatment. 
Chemotherapy was potentiated by E7449 and single agent had significant antitumor 
activity in BRCA-deficient xenografts. Additionally, E7449 inhibited Wnt/β-catenin 
signaling in colon cancer cell lines, likely through TNKS inhibition. Consistent with 
this possibility, E7449 stabilized axin and TNKS proteins resulting in β-catenin 
de-stabilization and significantly altered expression of Wnt target genes. Notably, 
hair growth mediated by Wnt signaling was inhibited by E7449. A pharmacodynamic 
effect of E7449 on Wnt target genes was observed in tumors, although E7449 
lacked single agent antitumor activity in vivo, a finding typical for selective TNKS 
inhibitors. E7449 antitumor activity was increased through combination with MEK 
inhibition. Particularly noteworthy was the lack of toxicity, most significantly the 
lack of intestinal toxicity reported for other TNKS inhibitors. E7449 represents a 
novel dual PARP1/2 and TNKS1/2 inhibitor which has the advantage of targeting 
Wnt/β-catenin signaling addicted tumors. E7449 is currently in early clinical 
development.
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INTRODUCTION
Poly(ADP-ribose) Polymerases (PARPs) catalyze 
the post-translational modification of proteins through 
addition of ADP-ribose, using nicotinamide adenine 
dinucleotide as substrate [1]. The PARP family comprises 
17 members, identified through sequence homology to 
the PARP1 catalytic domain. PARP1 and 2 and PARP5a 
and 5b (also known as tankyrase1 and 2; TNKS1 and 2) 
catalyze the addition of poly(ADP-ribose) (PAR), whereas 
the majority of family members incorporate single 
ADP-ribose units to substrate proteins [2, 3]. Covalent 
modification by the addition of PAR serves to regulate the 
function of target proteins, which often include the PARP 
enzymes themselves [4]. Large, linear and/or branched 
chains of PAR recruit binding proteins and serve as a 
scaffold for generation of large protein complexes [5, 6, 7].
PARP family enzymes are involved in many 
physiological processes, including cell division, regulation 
of transcription, maintenance of telomere integrity, 
control of protein degradation, and cell survival and 
death [8, 9]. Additional important functions in cellular 
stress responses include detection of DNA damage, DNA 
repair, response to heat shock, response to unfolded 
protein in the endoplasmic reticulum, and the cytoplasmic 
stress response [6, 8, 10, 11]. Discovered more than 40 
years ago, PARP1 is the founding member and the best 
characterized PARP [12, 13]. It is considered a significant 
anticancer target due to its important function in DNA 
damage repair and the maintenance of genomic stability 
as well as additional functions in transcriptional regulation 
and epigenetics [9, 14]. PARP1 is a highly abundant 
nuclear enzyme that is recruited to and activated by sites 
of DNA damage. PARP2 is similarly mobilized; however 
PARP1 activity is responsible for the majority (90–95%) 
of PAR generated by genotoxic stress [15, 16]. PARP1 
is involved in repair of single strand DNA breaks via the 
base excision repair (BER) pathway and non-homologous 
end joining (NHEJ) pathways [15, 17]. PARP1 inhibition 
in cancers defective in homologous recombination (HR) 
repair such as those containing mutations in BRCA1 
or BRCA2, leads to effective killing through synthetic 
lethality [18, 19]. In addition, preventing DNA repair 
through inhibition of PARP1/2 sensitizes tumor cells to 
radiotherapy and cytotoxic drugs that damage DNA, 
establishing a rationale for using PARP inhibitors as 
anticancer agents in combination therapy [14, 20]. Clinical 
proof of concept for synthetic lethality of PARP inhibitors 
in BRCA1/2 mutant breast and ovarian tumors has been 
achieved for olaparib (AstraZeneca) and niraparib (Tesaro) 
with sustained antitumor activity as monotherapy observed 
in patients with advanced disease [21, 22, 23, 24]. 
Olaparib (Lynparza) gained approval from the FDA 
and the European Medicines Agency for use in certain 
patients with advanced BRCA-mutated ovarian cancer. 
Additionally, various PARP inhibitors are under evaluation 
as combinatorial therapy in multiple clinical studies.
TNKS1 and 2 share high sequence similarity with 
PARP1 within their PARP catalytic domains, however 
the remainder of the proteins are highly divergent. 
Specifically, TNKS1 and 2 contain ankyrin repeats for the 
recognition and binding of substrate proteins and a sterile 
α-motif (SAM) that mediates protein-protein interaction 
and self-oligomerization [25, 26]. In contrast, PARP1 
comprises a DNA binding domain containing 2 Zn-finger 
motifs, a domain with a nuclear localization signal, and 
an auto-modification domain with a BRCT motif [1]. 
Knockout of genes encoding TNKS1 or 2 individually 
results in viable and developmentally normal mice, 
whereas inactivation of both genes is embryonic lethal, 
analogous to prior findings in PARP1 and 2 knockout 
mice [27, 28]. Tankyrases have multiple diverse cellular 
functions including regulation of Wnt/β-catenin signaling, 
and roles in telomere maintenance, mitosis and glucose 
uptake [25, 26]. At present, tankyrases are attracting 
significant attention as emerging therapeutic targets for 
cancer, principally due to their role in Wnt signaling. 
Aberrant Wnt/β-catenin signaling has been implicated 
in the development and progression of multiple cancers. 
Tankyrase inhibition results in stabilization of axin, a 
principal constituent of the β-catenin destruction complex, 
and culminates in antagonism of Wnt signaling [29].
Several PARP inhibitors are currently under 
evaluation in cancer patients. Phase 3 studies are underway 
and most are directed toward patients with BRCA mutant 
tumors. In this study, we describe the preclinical profile 
and characteristics of E7449, a novel and potent inhibitor 
of PARP1/2 and TNKS1/2. In common with earlier 
generation PARP1/2 inhibitors e.g. olaparib, niraparib, 
veliparib (AbbVie), etc., E7449 displays potent antitumor 
activity in BRCA-deficient in vivo models and potentiates 
the activity of chemotherapy preclinically. Inhibition 
of TNKS1/2 by E7449 is a significant distinction from 
traditional inhibitors and the resultant modulation of Wnt/
β-catenin signaling may broaden the potential therapeutic 
applications beyond tumors with deficient DNA repair 
capacity. Evaluation of E7449 in early clinical studies in 
cancer patients is underway [30].
RESULTS
E7449 inhibits PARP1 and 2 and TNKS1 and 2
E7449 is 8-(isoindolin-2-ylmethyl)-2,9-dihydro-
3H-pyridazino[3,4,5-de]quinazolin-3-one (Figure 1A, 
Supplemental Figure 1 for synthesis scheme); an orally 
bioavailable, brain penetrable, small molecule PARP 
inhibitor that is not a substrate for P-glycoprotein [31]. 
Potent inhibition of PARP was observed in a cell free assay 
(Trevigen) where PARylation of histones was inhibited by 
E7449 with IC
50
 values of 1.0 and 1.2 nmol/L for PARP1 
and 2 respectively (Supplementary Table 1). To examine 
selectivity of E7449 for PARP1 and 2, a screen of available 
full length recombinant human PARP enzymes was 
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performed using 32P-NAD+ as substrate and auto-PARylation 
as readout [2]. IC
50
 values of ~2.0 and ~1.0 nmol/L were 
obtained for E7449 inhibition of PARP1 and 2 respectively 
in this assay (Supplementary Table 1). Significant inhibitory 
activity was not observed for PARP3 or PARPs 6–16 
(PARP9 and 13 lack activity and PARP4 had minimal signal 
in this study, (data not shown)). In contrast, E7449 inhibited 
TNKS1 and 2 (PARP5a and 5b) with IC
50
 values of 50–100 
nmol/L (Supplementary Figure 2A, Supplementary Table 1). 
Assay of E7449 with the semi-quantitative TNKS1 histone 
PARylation assay from Trevigen revealed an average IC
50
 
value of 115 nmol/L for E7449 (Supplementary Table 1, 
Supplementary Figure 2B). In this assay the average IC
50
 
value for the selective tankyrase inhibitor XAV939, included 
as a positive control, was ~10 nmol/L (Supplementary 
Figure 2B), similar to that previously reported: 11 and 4 
nmol/L for TNKS1 and 2 versus 2.194 and 0.114 μmol/L 
for PARP1 and 2 respectively [29]. In contrast, the selective 
PARP1/2 inhibitor, olaparib (reported IC
50
 values of 5 and 1 
nmol/L for PARP1 and 2 versus 1.5 μmol/L for TNKS1 [32]) 
did not inhibit tankyrase at the concentrations tested; IC
50
 > 
3,000 nmol/L (Supplementary Figure 2B).
E7449 traps PARP1 onto DNA and affects DNA 
repair pathways beyond HR
In addition to catalytic inhibition of PARylation, 
mechanistic studies have recently revealed that PARP 
inhibitors may act as poisons to trap PARP onto DNA 
[33–35]. The PARP-DNA complexes likely interfere with 
Figure 1: E7449 traps PARP onto DNA and affects DNA repair pathways beyond HR. A. structure of E7449. B. western blot 
of chromatin-bound fraction from DT40 cells. Cells were treated with various concentrations of E7449 for 30 min or no drug (lanes 1 and 3)  
in the presence or absence of 0.05% MMS. Chromatin-bound proteins were extracted and subjected to western analysis using antibodies 
directed against PARP1 or Histone H3, a positive marker for chromatin-bound proteins. Graph represents quantification of PARP1 signal 
intensity, measured with Image Studio software on the LI-COR Odyssey imager. C. western blot of cells treated with olaparib in the 
presence or absence of 0.05% MMS; graph represents quantitation of PARP1 levels in chromatin-bound fraction. Representative images 
from 3 independent assays, where E7449 was assayed alongside olaparib. D. sensitivity profile of E7449 in a panel of 32 isogenic DNA 
repair mutant DT40 cell lines. Mean IC
50
 values from at least 3 independent assays were normalized to the IC
50
 value in wild type DT40 
cells (3.2 μmol/L). Bars are shaded based on DNA repair function; checkered for PARP1, grey for HR, white for NHEJ, and black for all 
other DNA repair pathways. Dashed lines represent 2-fold sensitivity or resistance of cell line to E7449 versus the wild type cells.
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DNA replication and thus, contribute to cytotoxicity. 
In avian B-lymphoblast DT40 cells damaged with the 
alkylating agent methyl methanesulfonate (MMS) the 
presence of E7449 resulted in binding of PARP1 to 
chromatin in a dose responsive manner (Figure 1B). 
Trapped PARP was also observed upon incubation of 
cells with olaparib (Figure 1C). Minimal PARP trapping 
was observed in the absence of MMS or PARP inhibitor 
(Figures 1B and 1C).
To further evaluate inhibition by E7449 and 
its selectivity for various DNA repair pathways, a 
cell proliferation assay was performed in a panel of 
32 isogenic DT40 cell lines, in which each line was 
deficient in a distinct DNA repair gene [36]. In wild type 
DT40 cells E7449 inhibited cell proliferation in a 2 day 
assay with an IC
50
 value of 3.2 μmol/L; this value was 
used for normalization of E7449 IC
50
 values obtained in 
mutant cells (Figure 1D, see Supplementary Figure 3 for 
representative IC
50
 curves). Strikingly, DT40 cells lacking 
PARP expression appeared significantly resistant to 
treatment with E7449, with a 5 fold increase in IC
50
 versus 
parental DT40 cells (Figure 1D). A similar observation was 
made with olaparib inhibition (Supplementary Figure 4): 
this finding is consistent with the requirement of PARP 
for drug cytotoxicity and the PARP trapping activity of 
both inhibitors. Notably, resistance to PARP inhibition was 
also observed in cells lacking Ku70, a protein required for 
NEHJ repair of double-strand DNA breaks. As anticipated, 
lines deficient in components of the HR pathway (BRCA1 
and 2, CtIP, Rad54, etc.) were most E7449-sensitive, with 
IC
50
 values up to 10 fold lower than those observed in wild 
type DT40 (Figure 1D). In addition, greater than  2 fold 
sensitization to E7449 was observed in cell lines deficient 
in checkpoints (ATM and RAD17), ubiquitin ligase for 
post-replication repair (RAD18), components of BER and 
nucleotide excision repair (NER) pathways; FEN1, POLD, 
and POLB, and the RecQ helicase BLM, confirming the 
extensive inhibitory activity of E7449 in DNA repair, 
outside the narrow definition of HR (Figure 1D). Overall, 
the sensitivity profile of E7449 closely resembled that 
determined for olaparib (Supplementary Figure 4).
E7449 potentiates antitumor activity of 
chemotherapies temozolomide and carboplatin
PARP1/2 inhibitors potentiate cell killing effects 
of DNA damaging chemotherapy through inhibition 
of DNA damage repair. Consistent and robust chemo-
potentiation of the alkylating agent temozolomide 
(TMZ) has been demonstrated with PARP1/2 
inhibition [14, 37, 38]. Potent sensitization of TMZ 
was established for E7449 in the mouse melanoma 
B16-F10 isograft model. Growth of subcutaneous 
tumors was moderately inhibited by single agent 
treatment with E7449 (100 mg/kg) or TMZ (50 mg/kg), 
whereas combination of E7449 dosed at 10, 30 and 
100 mg/kg with TMZ resulted in significantly enhanced 
tumor growth inhibition (Figure 2A). The increased 
antitumor activity was E7449 dose responsive and was 
significant even at the lowest E7449 dose of 10 mg/kg 
(Figure 2A). Potentiation of TMZ antitumor therapy was 
accompanied by increased toxicity as observed by 
decreased body weight in animals treated with the 
combination (Figure 2B). No animal lethality occurred 
but body weight loss was observed in all 3 combination 
groups. All mice recovered weight once treatment was 
completed.
Potentiation of platinum agents has also been 
reported for PARP1/2 inhibitors [14, 39]. In orthotopic 
MX-1 human breast cancer xenografts, treatment with 
E7449 enhanced the antitumor activity of carboplatin 
(Figure 2C). No antitumor activity was observed in 
MX-1 xenografts following treatment with E7449 alone 
at 100 mg/kg once daily and administration of a single 
dose of carboplatin resulted in only modest antitumor 
activity (Supplementary Figures 5A and 5B). Addition 
of E7449 resulted in enhanced carboplatin antitumor 
activity, but only when administered simultaneously 
with, or prior to carboplatin treatment (Figure 2C). E7449 
administration 1 day post-carboplatin treatment resulted 
in antitumor activity that closely resembled that observed 
with carboplatin alone. Combination treatment was well 
tolerated with no signs of toxicity or significant body 
weight loss observed for any of the treatments (Figure 2D).
Inhibition of PARP activity and growth of BRCA 
mutant tumors by E7449
A compelling body of evidence supports the use 
of PARP inhibitors in tumors lacking double stranded 
DNA repair by HR e.g. BRCA mutant tumors [reviewed 
in 14, 15]. To evaluate single agent antitumor activity, 
E7449 was assessed in a panel of breast cancer cell lines 
in an 8 day proliferation assay. E7449 sensitive and 
resistant lines were observed with IC
50
 values ranging 
from ~0.2 to >10 μmol/L (Figure 3A, see Supplementary 
Figure 6 for representative IC
50
 curves). MDA-MB-436, 
a triple negative breast cell line that harbors a BRCA1 
mutation (5396 +  1G > A in splice donor site of exon 
20) was the most sensitive cell line identified. In an 
in vivo subcutaneous MDA-MB-436 xenograft model, 
administration of E7449 at 30 or 100 mg/kg once daily 
for 28 days resulted in statistically significant antitumor 
activity (Figure 3B). A dose response was observed, with 
greater tumor growth inhibition at the higher 100 mg/kg 
dose. Treatment with E7449 at 30 or 100 mg/kg was 
well-tolerated without any significant body weight loss 
or deaths (data not shown). Pharmacodynamic PARP 
inhibition was assessed in tumors following a single dose 
of E7449 at 30 or 100 mg/kg (5 mice per group) at various 
time points post-dosing from 1 to 36 hours (Figure 3C 
and 3D). Considerable variability in PAR levels was 
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observed in the control (vehicle treated) group of 10 mice, 
as previously reported [40]. Treatment with E7449 at 
100 mg/kg resulted in significant PARP inhibition that 
was sustained for at least 12 hours and recovered to basal 
levels within 24 hours (Figure 3D). At the 30 mg/kg dose 
significant PARP inhibition was also observed but the 
effect was less sustained and partial rebound was observed 
within 12 hours (Figure 3C).
Pharmacodynamic PARP inhibition by E7449 
in tumors
To further interrogate E7449 pharmacodynamic 
PARP inhibition a study was conducted in the NCI-H460 
lung cancer xenograft model. No antitumor activity was 
recorded for E7449 in this model which was selected 
for its rapid and consistent tumor growth. Mice were 
administered a single E7449 dose from 1 to 100 mg/kg 
and tumors were harvested for PAR analysis by ELISA at 
various time points from 0.25 to 36 hours post-treatment. 
As in the previous study, significant variability in tumor 
PAR levels of vehicle-treated mice was noted (Figure 4, 
control mice panel). E7449 treatment resulted in 
significant PARP inhibition at early time points (0.25 and 
1 hour) even at the lowest administered dose of 1 mg/kg 
(Figure 4). PARP activity levels were recovered at least 
partially to basal levels within 6 hours post-dose of 
E7449 at 1 and 3 mg/kg. Increasing E7449 dose resulted 
in a more sustained duration of PARP inhibition. At the 
highest E7449 dose of 100 mg/kg complete inhibition 
was observed up to 12 hours and the rebound in activity 
delayed until 24 hours post treatment (Figure 4).
E7449 inhibits Wnt signaling in vitro
Tankyrase inhibition antagonizes Wnt/β-catenin 
signaling through axin stabilization, which results 
in enhanced activity of the destruction complex and 
Figure 2: E7449 potentiates antitumor activity of temozolomide and carboplatin. A. antitumor effect of E7449 in combination 
with TMZ in B16-F10 mouse melanoma isografts. Data represent the mean ± StdDev. TMZ was administered orally once daily for 5 days. 
E7449 was orally administered once daily in combination with TMZ for 5 days and alone for an additional 2 days. *P < 0.05 versus 
TMZ alone on days 14 and 20, #P < 0.05 versus vehicle control group on day 14 (one-way ANOVA followed by the Dunnett’s multiple 
comparison test). B. relative body weight of animals treated with E7449, TMZ, and E7449 + TMZ combination. Data represent the mean ± 
SEM. *Body weight loss was observed in all E7449 + TMZ combination treatment groups on day 7. Recovery from body weight loss was 
observed in all mice upon completion of drug treatment. C. antitumor effect of E7449 in combination with carboplatin in a MX-1 human 
breast cancer orthotopic model. Data represent the mean ± SEM. Carboplatin was administered as a single intravenous dose at 60 mg/kg on 
day 3 or 4. E7449 was orally administered once daily at 100 mg/kg with administration beginning on either day 3 or day 4. *P < 0.05 versus 
E7449 D4 + carboplatin D3 on day 19. D. relative body weights of animals treated with E7449 + carboplatin combination. No significant 
body weight loss was observed in any animals over the course of the experiment.
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ultimately in proteolysis of β-catenin [29]. Studies were 
performed to determine if E7449-mediated tankyrase 
inhibition could affect Wnt signaling in human colon 
cancer SW480 (Wnt active, APC mutant) cells in vitro. 
A significant increase in the level of axin2 protein 
was observed in cells treated with E7449 (Figure 5A). 
Increased axin2 was also observed following treatment 
with the selective tankyrase inhibitor XAV939, whereas 
axin2 remained at basal levels following treatment with 
the selective PARP1/2 inhibitor olaparib (Figure 5A). 
Stabilization of axin2 as well as tankyrase proteins 
appeared both E7449-dose and time responsive 
(Supplementary Figures 7A and 7B). Concomitant with 
the increase in axin2, E7449 treatment reduced levels 
of active (non-phosphorylated) and total β-catenin by 
~70 and 50% respectively, versus ~90 and 75% for the 
more potent XAV939 (Figures 5B and 5C). In contrast, 
β-catenin protein levels remained unchanged in olaparib-
treated cells (Figures 5B and 5C). A modest decrease in 
Cyclin D1 protein levels was observed following treatment 
with E7449 or XAV939, while protein levels were again 
unaffected by olaparib treatment (Figure 5D). Together 
Figure 3: Antitumor activity and PARP inhibition by E7449 in a BRCA mutant xenograft model. A. E7449 sensitivity 
profile for inhibition of proliferation in a breast cancer cell line panel. At least 3 independent assays were performed and data represent 
mean ± SEM. The most E7449-sensitive cell line, MDA-MB-436 (BRCA1 mutant) is shaded in black. B. antitumor effect of E7449 
in MDA-MB-436 human breast cancer xenografts. Data represent the mean ± StdDev. E7449 was administered orally once daily for 
28 consecutive days as indicated by shaded box. *P < 0.05 versus vehicle control group on day 83 (one-way ANOVA followed by the 
Dunnett’s multiple comparison test). C. and D. PARP inhibition by E7449 in tumor tissue from MDA-MB-436 human breast cancer 
xenografts. A single dose of E7449 at 30 mg/kg (Figure 3C) or 100 mg/kg (Figure 3D) was administered to animals bearing MDA-MB-436 
tumors. At various timepoints from 1 to 36 hours post-administration, animals were euthanized and tumors harvested. PARP activity in 
tumor lysate was assessed through determination of PAR levels, normalized by protein concentration. Mean PAR (ng/mg protein) in control 
animals (vehicle-treated) was set to 100% PARP activity and the inhibition of PARP activity for each time point was calculated by using an 
average of all control replicates. PAR % of control (mean ± SEM) was calculated from data of 2 experiments assayed in triplicate and each 
bar on the graph represents % PAR levels in the tumor tissue from an individual mouse.
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these data suggest that alterations in Wnt/β-catenin 
signaling proteins, mediated by E7449 and XAV939, are 
the consequence of tankyrase inhibition and accordingly 
were not observed with olaparib, which only weakly 
inhibits tankyrase.
In DLD-1 cells (Wnt active, APC mutant) treated 
with E7449, similar if less potent effects were observed 
on axin2 and cyclin D1; analogous to effects induced by 
XAV939, but not olaparib (Supplementary Figures 7C 
and 7D). A robust effect on levels of β-catenin was not 
observed by western blot for E7449 or XAV939 in this 
cell line. In the Wnt inactive human colon cancer RKO 
cell line, axin2 and β-catenin were not detected (data not 
shown).
Gene expression profiling was performed to measure 
the effect of E7449 treatment on expression of genes 
involved in Wnt signaling. Expression was measured by 
quantitative PCR using a custom-designed array following 
E7449 treatment of SW480 cells. Significantly altered 
expression of 30 Wnt-related genes was observed following 
E7449 treatment. Overall, the gene expression profile 
revealed by E7449 treatment closely resembled that obtained 
with XAV939 (Figure 6A). E7449-treated DLD-1 cells also 
underwent significantly altered expression of 40 Wnt-related 
genes and again, the expression heat map closely resembled 
that of XAV939 treated-cells (Supplementary Figure 8). 
Approximately 45% of genes altered upon E7449 treatment 
were common to both cell lines. PARP inhibitors are known 
to act as regulators of transcription factors [41]; therefore a 
study was conducted to confirm that gene changes observed 
were the result of tankyrase inhibition by E7449 and not 
PARP1/2 inhibition. SW480 cells were treated with E7449, 
XAV939 or olaparib (at 3 μmol/L where olaparib is not 
expected to inhibit tankyrases, as compared with 30 μmol/L 
in the previous study), and gene expression changes were 
measured using the array described above. Expression of 
17 Wnt-related genes was significantly altered by at least 
one of the 3 compound treatments (Figure 6B). Heat map 
expression profiles for E7449 and XAV939 were again 
highly comparable and differed considerably from that 
of olaparib, whose profile more closely resembled that of 
DMSO. Six E7449-responsive genes common to each study 
(NOS3, LGR5 and LEF1 up-regulated and NKD1, CYR61 
and MMP7, down-regulated) are represented in Figure 
6C and 6D. XAV939 treatment also altered expression of 
these 6 genes in the same direction, although differences 
in the scale of change were observed (Figure 6C and 6D). 
In contrast, olaparib treatment had no effect or altered 
expression in the opposite direction (NOS3, MMP7), 
(Figure 6D) suggesting that the E7449-mediated gene 
expression changes are the consequence of tankyrase 
inhibition.
Figure 4: Dose-dependent PARP inhibition by E7449 in tumor tissue from NCI-H460 human lung cancer 
xenografts. Mice were administered a single E7449 dose from 1 to 100 mg/kg or vehicle (control group). Mice were euthanized and 
tumors harvested for PAR analysis by ELISA at various time points from 15 min to 36 hours post-treatment. Normalization was performed 
as outlined in MDA-MB-436 study. PAR % of control (mean ± SEM) was calculated from data of 2 experiments assayed in triplicate. Each 
bar in graph represents % PAR level in the tumor tissue from an individual mouse.
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Figure 5: E7449 inhibits Wnt signaling in vitro: effects of E7449 treatment on Wnt proteins in SW480 cells by western 
blot analysis. Following 24 h incubation of cells with indicated compounds at 10 μmol/L, cell lysates were subjected to electrophoresis 
and western blot, then probed with antibodies targeting various Wnt/β-catenin pathway proteins: A. axin2; B. total β-catenin; C. active 
(non-phosphorylated) β-catenin; D. cyclin D1. Tubulin was used as a sample loading control and fluorescence intensity of bands was 
measured using Image Studio software on the LI-COR Odyssey imager. Ratio of analyte to tubulin was plotted (A–D, right hand panels) 
and each is a representative of several independent experiments.
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E7449 inhibits Wnt signaling in vivo
Wnt signaling is necessary for hair follicle 
development and cycling [42–44]. Re-growth of hair in 
mice was investigated to determine if tankyrase inhibition 
by E7449 could impact Wnt signaling in vivo. Following 
hair removal, C57BL/6 mice were treated with E7449 
administered once daily at 30, 100 or 300 mg/kg. Within 2 
weeks, notable re-growth of hair was observed in vehicle-
treated mice with only a few small bald patches remaining; 
full hair re-growth was observed by Day 21 (Figure 7). In 
contrast, hair re-growth was significantly delayed in mice 
treated with E7449. A dose response effect was observed 
and bald patches remained at Day 21 in mice treated with 
the higher E7449 doses (Figure 7). These data suggest 
inhibition of Wnt signaling in vivo mediated by E7449, 
likely through inhibition of tankyrase activity.
E7449 combined with MEK inhibitor inhibits 
tumor growth in a Wnt model
In a Wnt1 subcutaneous model (mammary tumors 
initially isolated from Wnt1 (int-1) transgenic mice [45]), 
single agent E7449 treatment (100 mg/kg) did not inhibit 
tumor growth whereas significant antitumor activity 
was observed following administration of the porcupine 
inhibitor Wnt-C59, a potent Wnt signaling antagonist 
(Figure 8A). Gene expression analysis in tumors from 
Figure 6: E7449 inhibits Wnt signaling in vitro: effects of E7449 treatment on expression of Wnt-related genes in 
SW480 cells. A. following 72 h incubation of SW480 cells with E7449 or XAV939 at 30 μmol/L or DMSO (control), RNA was harvested 
and gene expression profiling performed using a custom designed TLDA; genes listed in Supplementary Table 2. The heat map represents 
30 Wnt-related genes whose expression was altered following E7449 exposure (red: increased, green: decreased). Genes with a relative 
fold change of ≥ 1.5 (P > 0.05, student’s t-test) versus DMSO control were subjected to hierarchical clustering (Manhattan distance) and 
complete linkage plotting to generate the heat map. B. Gene expression profiling in SW480 cells treated with E7449, XAV939 or olaparib 
at 3 μmol/L or DMSO for 72 h. Heat map generated as above represents 17 Wnt-related genes whose expression was significantly altered by 
any of the 3 compound treatments. C. and D. 6 E7449-responsive genes common to both 3 and 30 μmol/L study respectively; data represent 
mean ± SEM. In general, XAV939 treatment altered gene expression in the same direction as E7449, whereas olaparib treatment had no 
effect or altered expression in the opposite direction (D).
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Wnt-C59-treated mice revealed significant alteration of 
several Wnt-related genes including CAR2, FZD9, LEF1, 
and VIL1 (Figure 8B). Expression of these genes was 
also altered in tumors from E7449-treated mice, albeit to 
a lesser extent (Figure 8B). Tankyrase inhibition of Wnt 
signaling by itself may prove insufficient to achieve tumor 
shrinkage; therefore, activity of E7449 was re-assessed in 
combination with the MEK inhibitor E6201. Antitumor 
activity was enhanced in the combination versus either 
single agent alone (Figure 8C, left panel). The addition 
of E7449 to E6201 had minimal effect on toxicity as 
measured by body weight loss (Figure 8C, right panel).
DISCUSSION
This report provides the first characterization of a dual 
PARP1/2 and TNKS1/2 inhibitor. E7449 is a novel, potent 
inhibitor of the DNA repair proteins PARP1 and 2; it traps 
PARP onto DNA to augment cytotoxicity and, comparable 
to earlier PARP inhibitors it exhibits selectivity for tumor 
cells that are deficient in HR repair and other DNA 
repair pathway proteins. Single agent antitumor activity 
was observed for E7449 in a BRCA mutant xenograft 
model, while in combination E7449 potentiated the DNA 
damaging effects of chemotherapy in vivo. Additionally, 
and in contrast to described clinical PARP inhibitors, E7449 
inhibits the PARylation activity of TNKS1/2 at a clinically 
relevant dose. Tankyrase is a key regulator of Wnt/β-catenin 
signaling, a pathway known to promote tumorigenesis and 
a target for the development of cancer therapeutics. In 
cells with active Wnt signaling, E7449 treatment altered 
expression of Wnt pathway proteins and Wnt-related 
genes, and administration to mice prevented re-growth of 
hair, a Wnt-dependent pathway. Pharmacodynamic effects 
on Wnt signaling were observed in the Wnt1 model, and 
co-administration of E7449 with a MEK inhibitor, resulted 
in a synergistic antitumor effect, with no significant toxicity. 
Dual inhibition of TNKS1/2 and PARP1/2 distinguishes 
E7449 from existing PARP inhibitors and may lead to a 
distinct spectrum of clinical opportunity; E7449 is currently 
in early phase clinical development [30].
E7449 inhibits PARP1 and 2 with a potency 
of 1.0 and 1.2 nmol/L; values in a similar range to 
those reported for olaparib, niraparib and talazoparib 
(BioMarin), with the caveat that different assays were 
used for each inhibitor [32, 46, 47]. PARP trapping was 
demonstrated for E7449 in DT40 cells in the presence 
of the alkylating agent MMS. A dose responsive effect 
was observed, however the increase in trapped PARP 
appeared minimal alongside the 100 fold increase in 
E7449 concentration (Figure 1B), perhaps because 
PARP trapping was close to maximal at the lowest 
E7449 treatment (0.1 μmol/L), or reflecting the limit of 
sensitivity of the assay. The amount of PARP detected 
in chromatin complexes was almost identical for E7449 
and olaparib. Beyond the similar potency of catalytic 
inhibition and PARP trapping by E7449, the dose of 
E7449 necessary for sustained PARP inhibition in 
Figure 7: E7449 dose-responsively inhibits re-growth of hair, a Wnt-mediated pathway, in mice. C57BL/6 female mice 
were depilated using Nair™ and E7449 treatment initiated the following day. E7449 was administered at 30, 100 or 300 mg/kg once daily 
for 12 days. Re-growth of hair was monitored and recorded by photography for comparison to vehicle-treated mice.
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tumors and single agent antitumor activity closely 
resembles that described for the traditional PARP 
inhibitors, olaparib, niraparib, etc. rather than the lower 
dosed talazoparib [32, 46, 47].
Data generated in the DT40 cell line panel 
where PARP deficient cells were significantly more 
resistant to E7449 than wild type cells demonstrate 
the requirement of PARP for E7449 activity and also 
confirm E7449-mediated PARP trapping to enhance 
cytotoxicity. Resistance to E7449 was also observed 
in cell lines deficient in NHEJ repair (KU70, PKCS, 
and LIGlV) as previously reported for other PARP 
inhibitors [35]. Predictably, cell lines that lacked HR 
pathway proteins were more sensitive to E7449, and an 
increase in susceptibility to E7449 was also observed 
in cell lines with deficiency in checkpoint proteins and 
well as proteins from several DNA repair pathways, 
including BER and NER. The profile of E7449 in the 
panel is indistinguishable to that of olaparib, again 
demonstrating that the PARP1/2 inhibition properties 
of E7449 closely correlate to those of traditional PARP 
inhibitors.
While E7449 closely parallels previously described 
inhibitors in terms of PARP inhibition and preclinical 
properties, significant divergence arises with respect to 
effects on tankyrase activity. E7449 inhibits TNKS1/2 
with IC
50
 values from 50 to 120 nmol/L, a dose considered 
clinically relevant [30]. An IC
50
 value of > 3 μmol/L was 
determined for olaparib for TNKS1 inhibition using the 
Trevigen assay. Reported IC
50
 values for tankyrase inhibition 
by olaparib, niraparib, and veliparib (various assays) are 
at least 5–20 fold higher than that observed for E7449 
(1.5 μmol/L, 0.6 μmol/L, and 15 μmol/L, respectively 
[32, 46, 25]), and reflect drug concentrations not likely to 
be achievable clinically. No data have been reported for 
tankyrase inhibition by rucaparib or talazoparib, although 
rucaparib binding to the catalytic domain of multiple PARP 
family members including tankyrases was described by 
Wahlberg et al [48]; no significant binding of TNKS1/2 was 
reported for olaparib or veliparib in their study.
Figure 8: Antitumor effect of E7449 in combination with MEK inhibitor in Wnt-dependent model. A. effect of E7449 on 
tumor growth in Wnt1 subcutaneous model. No antitumor effect was observed following administration of E7449 once daily at 100 mg/kg. 
Wnt-C59 porcupine inhibitor dosed once daily at 10 mg/kg significantly inhibited tumor growth (left panel). Both drugs were well tolerated 
with minimal toxicity as measured by body weight loss (right panel). B. Relative fold change in expression of CAR2, FZD9, LEF1, and 
VIL1 in tumors harvested following 7 days of drug treatment. Analysis was performed using a mouse-specific TLDA (genes listed in 
Supplementary Table 3) and data for individual tumors are plotted (5 mice per group), with lines representing median. * P > 0.05, student’s 
t-test with fold change of ≥ 2. C. synergistic antitumor activity with combination of E7449 and MEK inhibitor E6201 in Wnt1 model. E7449 
was administered orally once daily and E6201 was administered intravenously Q4Dx3. No antitumor activity was observed with single 
agent E6201; combination with E7449 resulted in synergistic inhibition of tumor growth (left panel). E6201 treatment resulted in decreased 
body weight (<10%) which recovered post-treatment. Addition of E7449 to E6201 did not impact body weight loss (right panel).
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While tankyrases perform multiple and varied 
cellular tasks including maintenance of telomeres, roles 
in mitosis and glucose uptake, the burgeoning interest 
in targeting tankyrase for development of anticancer 
therapeutics is primarily directed to their role in the 
regulation of Wnt/β-catenin signaling [25, 26]. The 
β-catenin destruction complex (composed of APC, axin 
(limiting component), and GSK3β) regulates proteolysis of 
the transcription factor β-catenin through phosphorylation 
and is inactivated during active Wnt signaling; this 
leads to accumulation of non-phosphorylated β-catenin 
that translocates to the nucleus and transcribes multiple 
target genes, including cyclin D1. PARylation of axin by 
tankyrase is necessary for its subsequent ubiquitination 
by RNF146 and proteasome degradation; inhibition 
of tankyrase by XAV939 results in axin and tankyrase 
stabilization, enhanced activity of the destruction complex 
and ultimately in inhibition of β-catenin-mediated 
transcription [25, 29, 49]. Wnt/β-catenin signaling 
perturbation was achieved with E7449 treatment in Wnt-
active colon cancer cells and the profiles generated both by 
western blot and in gene expression studies appeared very 
similar to that of the selective tankyrase inhibitor XAV939. 
Importantly and distinctly, treatment with olaparib which 
lacks potent tankyrase inhibition had minimal impact on 
Wnt signaling proteins in these in vitro studies, implying 
that effects were not PARP1/2-sensitive and were more 
likely the result of tankyrase inhibition. Additionally, 
E7449 treatment prevented re-growth of hair in mice, 
a process that is Wnt signaling dependent [42–44]. We 
postulate that E7449 reduces Wnt/β-catenin signaling 
by inhibiting tankyrase, thus preventing PARylation-
dependent axin degradation, and thereby promoting 
β-catenin destabilization.
Tankyrase is currently the most highly validated 
druggable target in the Wnt/β-catenin pathway; inhibitors 
have been shown to reduce signaling and extensive 
discovery efforts have resulted in the identification of 
multiple tankyrase inhibitors [reviewed in 25, 26]. Of 
these, only G007-LK was reported to inhibit tumor 
growth as a single agent in certain models [50], while 
the majority of tankyrase inhibitors lack antitumor 
activity in vivo. Similarly, E7449 treatment resulted in 
pharmacodynamic effects on Wnt-target genes in vivo but 
these changes in gene expression appeared insufficient to 
mediate an antitumor effect in the Wnt1 model as a single 
agent. G007-LK has a very narrow therapeutic window 
because of intestinal toxicity, an on-target tankyrase 
inhibition effect [50]. Dose limiting intestinal toxicity that 
produces significant adverse effects is commonly observed 
upon inhibition of Wnt/β-catenin signaling [51, 52]. 
Importantly, no gastrointestinal toxicity was observed in 
preclinical studies with E7449 despite evidence of Wnt-
target perturbation. Moreover, E7449 has been generally 
well tolerated in cancer patients treated to date, with 
fatigue (a PARP inhibitor class effect) rather than intestinal 
toxicity identified as the dose-limiting toxicity in a small 
phase 1 study [30].
Wnt/β-catenin signaling has been identified as a 
potential mediator of resistance to MEK inhibition and 
strong synergy has been observed for the combination of 
MEK and tankyrase inhibition in KRAS-mutant cancer 
cells [50, 53, 54]. Consistent with these findings, when 
E7449 was combined with the MEK inhibitor, E6201, 
synergistic antitumor activity was observed in the Wnt1 
model. E7449 also significantly potentiated the antitumor 
effects of temozolomide and carboplatin with tolerable 
toxicity, most likely through inhibition of DNA repair 
activity of PARP1/2. In addition to a wide range of 
chemotherapeutic agents, PARP inhibitors are increasingly 
under clinical investigation in combination with targeted 
therapies including inhibitors of PI3K, bortezomib, 
etc. Co-inhibition of TNKS1/2 by E7449 potentially 
increases the range and number of possible, rationally 
targeted combinations for this therapy. For example, a 
critical role for tankyrase and Wnt/β-catenin signaling 
was identified for maintenance of lung cancer cells during 
EGFR inhibition and subsequent inhibition of tankyrase 
significantly enhanced the antitumor activity of EGFR 
inhibitors in NSCLC cells [55]. Testing additional targeted 
therapies with E7449 may reveal novel combinations and 
indications for further development.
In this study we illustrate the unique properties 
of E7449, a multi-targeted drug. We provide evidence 
for meaningful inhibition of the DNA repair PARPs, 
PARP1/2, in addition to TNKS1/2, key components of 
Wnt signaling. Inhibition of multiple anticancer targets 
offers the potential for enhanced efficacy and expanded 
indications or combination partners, versus a single target 
drug. Multi-target agents are common in drug discovery 
and promiscuous multi-kinase inhibitors have proved 
therapeutically effective anticancer drugs; using this as an 
example, we propose that E7449 may possess increased or 
broader therapeutic effectiveness through its dual PARP/
TNKS inhibition.
MATERIALS AND METHODS
Reagents
Synthesis of E7449 (C
18
H
15
N
5
O; IUPAC 
8-(isoindolin-2-ylmethyl)-2,9-dihydro-3H-
pyridazino[3,4,5-de]quinazolin-3-one is described in the 
supplementary methods and structures of intermediates 
are provided in Supplementary Figure 1. E7449 and 
E6201 (Eisai Inc.) stock solutions were prepared in 
dimethyl sulfoxide (DMSO), aliquoted and stored at 
−20oC. Olaparib and XAV939 were obtained from Selleck 
Chemicals. Temozolomide (TMZ) was obtained from LKT 
Laboratories (Cat# T1849).
A panel of 32 isogenic DT40 cell lines [36], in 
which each line was deficient in a distinct DNA repair 
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gene was maintained and assays were performed in the 
laboratory of Dr. Jun Nakamura, UNC. MX-1 cells were 
obtained from National Cancer Institute (Bethesda, MD). 
All other cell lines were obtained from American Type 
Culture Collection (ATCC) and maintained according 
to their instructions. For in vivo studies, cells were used 
within a short time of receipt from ATCC or cell line 
authenticity was verified by STR typing.
PARP and TNKS enzyme assays: catalytic 
inhibition and PARP trapping
The ability of E7449 to inhibit the activity of 
human recombinant PARP1, mouse recombinant PARP2 
or human recombinant TNKS1 was determined using 
chemiluminescent PARP or tankyrase assay kits from 
Trevigen, following the manufacturer’s instructions. IC
50
 
values were determined by non-linear regression using the 
GraphPad Prism 5 software version 5.02 (Lake Forest, CA).
DT40 cells [36] were treated with PARP inhibitor 
(0.1–10 μmol/L) in combination with 0.05% Methyl 
methanesulfonate (MMS, Sigma-Aldrich (Cat# 129925). 
Cells were pretreated for 5 min with MMS prior to adding 
PARP inhibitor for a further 30 min incubation at 37oC 
with gentle shaking. Following treatment, cells were lysed 
using the subcellular protein fractionation kit for cells 
(Thermo Scientific, Cat# 78840) to obtain the chromatin-
bound fraction. Chromatin-bound proteins were subjected 
to western blot analysis with antibodies against PARP1 
(Cell signaling Technology (CST), Cat# 9532), and 
histone H3 as control (CST Cat# 3638). Following binding 
of appropriate secondary antibodies labeled with IRDye® 
(LI-COR), image analysis and quantitation of blots was 
performed with Image Studio software for the LI-COR 
Odyssey system (version 2.1.10).
GFP-PARPs were expressed in 293F cells 
and the auto-PARylation activity of each PARP was 
assessed in the presence or absence of E7449 at various 
concentrations as in the previously described assay [2]. 
Briefly, 24 to 48 h after transfection, cells were washed 
3x in ice-cold PBS and lysed for 20 min on ice in cell 
lysis buffer (CLB: 50 mM HEPES, pH 7.4, 150 mM NaCl, 
1 mM MgCl
2
, 1 mM EGTA, 1 mM DTT, 1% TritonX-100, 
1 μg/mL leupeptin, aprotinin, pepstatin, PMSF). Lysates 
were subject to ultracentrifugation at 100,000 g for 30 min. 
Cleared lysates were incubated for 1 h at 4oC with anti-
GFP antibody (3E6, Life Technologies) and pre-bound 
protein A magnetic beads (Millipore). Beads were then 
washed 1 × 5 min in CLB, followed by 3 × 10 min washes 
in CLB containing 1 M NaCl, and 1 × 5 min wash in PARP 
reaction buffer (PRB; 50 mM Tris, pH 7.5, 50 mM NaCl, 
0.5 mM DTT, 0.1% TritonX-100, 1 μg/mL leupeptin, 
aprotinin, pepstatin). NAD+ incorporation reactions 
were performed in PRB containing 10 μmol/L NAD+ 
supplemented with 32P-NAD+ at 1:20 ratio for 30 min 
at 25oC. For PARPs with low incorporation signals 
(PARP4, 5a and 16), NAD+ incorporation was performed 
at 1:5 ratio for 1 h at 25oC. Beads were then re-suspended 
in Laemmli sample buffer, heated to 65oC for 10 min, 
the beads removed using a magnet, and the supernatant 
spotted onto Whatman paper. Samples were analyzed via 
phosphorimaging.
Cell lines and proliferation assay
Proliferation assays were performed in a panel of 32 
isogenic DT40 cell lines, in which each line was deficient 
in a distinct DNA repair gene [36]. Cells were seeded and 
incubated with test compound at various concentrations 
for 2–3 days (~ 8 cell cycles). Cell growth was assessed 
using XTT (ATCC® Cat# 30–1011K™) and IC
50
 values 
were calculated using the GraphPad Prism 5 software 
version 5.02 (Lake Forest, CA). Each experiment was 
conducted in duplicate and a minimum of 3 separate 
experiments were performed. Human breast cancer cell 
lines, HCC1143, HCC70, HCC1806, MDA-MB-436, 
T47D, MDA-MB-157, MDA-MB-231, MDA-MB-468, 
MDA-MB-453, BT-20 and Hs578T were obtained from 
ATCC. For cell line panel assays, cells were maintained 
and assayed in RPMI 1640 or DMEM medium containing 
10% FBS. For proliferation assays cells were plated at 
low density in 96 well plates. E7449 was added at various 
concentrations and plates incubated for a total of 8 days; 
compound and medium were replenished on day 4. 
Cell growth was assessed using the CellTiter-Glo® cell 
viability assay (Promega, Cat# G7573). Each experiment 
was conducted in duplicate and a minimum of 3 separate 
experiments were performed.
Western blot and Gene expression
SW480, DLD-1 (Wnt-dependent) or RKO (Wnt-
independent) cells were plated in 6-well plates and 
incubated overnight. Cells were treated with E7449, 
olaparib or XAV939 and incubated for various time 
periods prior to processing by SDS PAGE and western blot 
analysis. Blots were probed with antibodies to axin 2 (CST 
Cat# 2151), total β-catenin (CST Cat# 8480), non-phospho 
(active) β-catenin (CST Cat# 8814), cyclin D1 (CST 
Cat# 2926, Cat#2978), tankyrase (Abcam Cat# ab13587: 
this antibody does not discriminate between tankyrase 
1 and 2), α-tubulin (Abcam Cat# ab56676), and β-actin 
(Abcam Cat# ab3280). Following binding of appropriate 
secondary antibodies labeled with IRDye® (LI-COR), 
image analysis was performed with Image Studio software 
for the LI-COR Odyssey system (version 2.1.10).
Gene expression profiling was performed using a 
custom designed TaqMan® low density array (TLDA). 
Total RNA was isolated from cell lines using RNeasy 
Mini Kit (Qiagen) and from xenograft tumor FFPE 
tissue using RecoverAll Total Nucleic Acid Isolation 
(Ambion). Human and mouse, real-time qPCR TLDAs 
Oncotarget41320www.impactjournals.com/oncotarget
(384-well micro fluidic card) were designed with genes 
selected based on their involvement in Wnt signalling 
(see supplementary Tables 2 and 3 for lists of genes on 
TLDAs). cDNA was generated from total RNA using 
High Capacity cDNA Reverse Transcription kit (Life 
Technologies) or SuperScript® VILO™ Master Mix (Life 
Technologies). 100 ng cDNA was combined with TaqMan® 
Gene Expression Master Mix (Life Technologies) for the 
cell lines and TaqMan® Advanced FAST Master Mix 
(Life Technologies) for the xenograft tissue for each port 
(in duplicate). TLDAs were run based on recommended 
cycling times for each master mix. Ct values were 
calculated and imported into GeneData Analyst for further 
analysis. To calculate the ΔCts, gene expression was 
normalized to several housekeeping genes. Relative fold 
change was calculated by comparison to the DMSO or 
vehicle-treated controls for each sample. A student’s t-test 
was used to calculate P-values and hierarchical clustering 
used Manhattan distance and complete linkage plotting of 
selected significant genes to generate heat maps.
In vivo efficacy studies
All studies were performed according to IACUC 
approved protocols. The general health of mice was 
monitored daily. Tumor volume was determined by caliper 
measurements (mm), using the formula (l x w2)/2 = mm3, 
where l and w refer to the larger and smaller perpendicular 
dimensions collected at each measurement. Tumor 
dimensions were recorded twice per week starting when 
tumors reached an approximate size of 100 to 150 mm3. 
Body weights were recorded twice per week and relative 
body weight was calculated as follows: Relative body 
weight = (body weight on day of measurement/ body 
weight on first day of treatment).
TMZ combination in B16-F10 isograft model: 
female C57BL/6 mice were inoculated subcutaneously 
with B16-F10 cells (2 × 105). Following randomization 
by body weight, drug treatment was initiated 1 day post-
inoculation. Both E7449 and TMZ were formulated in 
0.5% methyl cellulose and orally administrated once 
per day. TMZ was administered daily on days 1 to 5 at 
50 mg/kg as a single agent or in combination. E7449 was 
administered daily on days 1 to 7 at doses of 10, 30 and 
100 mg/kg in combination with TMZ and at a dose of 
100 mg/kg as a single agent. The control group was treated 
with vehicle (0.5% methyl cellulose in water). E7449 or 
vehicle was administered first and when dosing of all 
animals was complete TMZ was administered to animals 
receiving the combination.
Carboplatin combination in MX-1 orthotopic 
xenografts: female nude mice were implanted with 
MX-1 cells (0.5 × 106) in the thoracic mammary fat pad. 
Treatment started on day 3 when the average tumor size 
was approximately 50 mm3. Carboplatin was administered 
as a single intravenous dose at 60 mg/kg on day 3 or 4. 
E7449 was administered orally once daily at 100 mg/kg 
with administration beginning on either day 3 or day 4.
E7449 as a single agent in MDA-MB-436 
xenografts: female SCID mice were inoculated 
subcutaneously with MDA-MB-436 cells (1 × 107). 
E7449 treatment was initiated on day 46 post-inoculation 
and continued once daily for 28 days at doses of 30 or 
100 mg/kg.
E6201 and E7449 combination in Wnt1 model: 
Mammary tumors were initially isolated from Wnt1 
(int-1) transgenic mice [45] and the model maintained 
through serial passage of tumor pieces. Tumor pieces 
cut to approximately 2 mm3 in size were injected 
subcutaneously in female nude mice. Treatment was 
initiated approximately 9–10 days post-implantation of 
mice. E7449 was administered once daily at 100 mg/kg, 
alone or in combination with E6201 (MEK inhibitor), 
administered intravenously every 4 days 3 times at 
40 mg/kg. The porcupine inhibitor Wnt-C59 (BioVision 
Cat# 2063) which inhibits Wnt signaling was included as 
a positive control and dosed orally once daily at 10 mg/kg 
(formulated in 0.5% methyl cellulose with 0.1% Tween 80).
Seven week old C57BL/6 female mice were 
subjected to depilation using Nair™ to examine any 
effect of E7449 on re-growth of hair. Drug treatment was 
initiated the next day and E7449 was dosed at 30, 100 or 
300 mg/kg orally once daily for 12 days. Re-growth of 
hair was monitored and recorded by photography.
In vivo PARP inhibition
Inhibition of PARP activity was evaluated in tumor 
lysates from MDA-MB-436 xenograft mice following 
administration of a single dose of E7449 at 30 or 100 mg/kg. 
Control group (10 mice) were treated with vehicle (0.5% 
methyl cellulose in water). Mice were euthanized and 
tumors were harvested at 1, 6, 12, 24 and 36 hours post 
treatment (5 mice per treatment per time point). Individual 
tumors were removed and flash frozen in liquid nitrogen 
for PAR analysis. PARP inhibition was also evaluated in 
tumors from NCI-H460 human lung cancer subcutaneous 
xenografts. Control group animals (24 mice) were 
treated with vehicle (0.5% methyl cellulose). E7449 was 
administered in a single dose at 1, 3, 10, 30 and 100 mg/kg. 
Mice were euthanized and tumors were harvested at 0.25, 
1, 6, 12, 24 and 36 hours post-treatment. PAR levels were 
determined by ELISA using the procedure provided by 
Trevigen and comparing to a PAR standard curve. Protein 
concentration of tumor lysates was determined using the 
BCA assay (Thermo Scientific). Results were converted 
from pg PAR/assay well to ng PAR/mg protein. Data was 
pooled from multiple experiments. The percent of control 
for each time point was calculated by using an average of 
all control replicates from that experiment.
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